Antidepressant medication in the treatment of agoraphobia: a critical review.
D000379:Agoraphobia / Q000188:drug therapy* / Q000628:therapy; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001521:Behavior Therapy / Q000379:methods; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003887:Desensitization, Psychologic; D004311:Double-Blind Method; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010349:Patient Compliance; D010624:Phenelzine / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy*; D011613:Psychotherapy / Q000379:methods; D012107:Research Design; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D013997:Time Factors
D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D002997:Clomipramine; D010624:Phenelzine; D007099:Imipramine